Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.
Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.
复制标题
DOI：
10.1186/s13287-017-0598-y
复制
发表时间：
2017-06-15
影响因子：
7.5
通讯作者：
Majumdar AS
中科院分区：
文献类型：
--
作者：
Bora P;Majumdar AS
脂肪/脂肪组织提供了用于立即施用的基质血管部分（SVF）细胞的丰富来源，并且还可以产生大量培养的多能脂肪源性基质细胞（ADSC）。最近，SVF和ADSCs在再生医学中获得了广泛的转化意义。最初用于美容丰胸，这种治疗模式已发现用于许多疾病，包括免疫紊乱，组织变性和缺血性疾病。在这篇综述中，我们试图解决该领域的几个重要方面，概述与基于SVF和ADSC的疗法相关的生物学、技术、翻译和挑战。从SVF和ADSC隔离的基础知识开始，我们触及最近开发的技术，解决正在开发的SVF即时隔离的新方法和设备的元素。SVF细胞和ADSC的表征也是一个不断发展的领域，我们将CD 34抗原的异常表达作为一个有趣的标志物。基于涉及SVF的不同细胞的报告，我们得出了一个潜在的作用模式，专注于血管生成，因为它涉及多个细胞，不像免疫调节主要由ADSC控制。我们已经研究了最新的研究，实验疗法和临床试验，这些试验利用SVF/ADSC治疗多发性硬化症，克罗恩病，周围神经病变，骨关节炎，糖尿病足溃疡等疾病。然而，由于缺乏针对此类疗法的适当监管指南，出现了问题，并且自从美国食品和药物管理局（FDA）引入指南草案和“改善健康的再生健康选择的可靠有效增长”（REGROW）法案以来，关于这些细胞的安全和有效使用的辩论变得更加公开。
Adipose/fat tissue provides an abundant source of stromal vascular fraction (SVF) cells for immediate administration and can also give rise to a substantial number of cultured, multipotent adipose-derived stromal cells (ADSCs). Recently, both SVF and ADSCs have gained wide-ranging translational significance in regenerative medicine. Initially used for cosmetic breast enhancement, this mode of treatment has found use in many diseases involving immune disorders, tissue degeneration, and ischaemic conditions. In this review, we try to address several important aspects of this field, outlining the biology, technology, translation, and challenges related to SVF- and ADSC-based therapies. Starting from the basics of SVF and ADSC isolation, we touch upon recently developed technologies, addressing elements of novel methods and devices under development for point-of-care isolation of SVF. Characterisation of SVF cells and ADSCs is also an evolving area and we look into unusual expression of CD34 antigen as an interesting marker for such purposes. Based on reports involving different cells of the SVF, we draw a potential mode of action, focussing on angiogenesis since it involves multiple cells, unlike immunomodulation which is governed predominantly by ADSCs. We have looked into the latest research, experimental therapies, and clinical trials which are utilising SVF/ADSCs in conditions such as multiple sclerosis, Crohn’s disease, peripheral neuropathy, osteoarthritis, diabetic foot ulcer, and so forth. However, problems have arisen with regards to the lack of proper regulatory guidelines for such therapies and, since the introduction of US Food and Drug Administration draft guidelines and the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act, the debate became more public with regards to safe and efficacious use of these cells.